The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of the novel fas ligand (FasL) inhibitor M3T01 in adults with advanced solid tumors.
 
Rom Leidner
Consulting or Advisory Role - AstraZeneca; CDR-Life; RAPT Therapeutics; Vir
Research Funding - Incyte (Inst)
Patents, Royalties, Other Intellectual Property - Lucid Diagnostics
Other Relationship - Incyte
 
Prakash Ambady
Employment - Providence Health and Services
Stock and Other Ownership Interests - Ashwathi Clinical Strategies LLC; Wyeast Biotech Inc
Honoraria - SERVIER; SpringWorks Therapeutics
Consulting or Advisory Role - SERVIER; SpringWorks Therapeutics
Patents, Royalties, Other Intellectual Property - Morpholino oligonucleotides useful in cancer treatment Patent number: 11679121 Abstract: Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides,; US11679121B2; US11679121B2
 
Emily Lin
Employment - Providence Cancer Institute
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Natera (Inst); Pfizer (Inst); Seagen (Inst); Surface Oncology, Inc (Inst)
Travel, Accommodations, Expenses - Incyte; Natera
Other Relationship - MDOutlook; Research to Practice
 
Neda Jooya
No Relationships to Disclose
 
Amber Ruiz
No Relationships to Disclose
 
Christopher Darus
Consulting or Advisory Role - Abbvie; AstraZeneca; Corcept Therapeutics; Daiichi Sankyo/Lilly; Eisai
Travel, Accommodations, Expenses - Gilead Sciences; Regeneron
 
Cassandra Niemi
No Relationships to Disclose
 
Binbin Zheng-Lin
No Relationships to Disclose
 
Tara Foote
No Relationships to Disclose
 
Ashley Drokin
No Relationships to Disclose
 
Alex Tran
No Relationships to Disclose
 
Grayson DuRaine
No Relationships to Disclose
 
Douglas Hanes
No Relationships to Disclose
 
William Redmond
Consulting or Advisory Role - Medicenna; Vesselon
Research Funding - Bristol-Myers Squibb (Inst); Galecto (Inst); InhibRx (Inst); Shimadzu (Inst)
Patents, Royalties, Other Intellectual Property - Galectin Therapeutics
 
Bernard Fox
Employment - UbiVac (I)
Leadership - UbiVac
Stock and Other Ownership Interests - PrimeVax; Turnstone Bio; UbiVac
Honoraria - Calidi Biotherapeutics; Incyte; Merck; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Turnstone Bio
Research Funding - Hamamatsu Photonics; Incyte; Shimadzu
Patents, Royalties, Other Intellectual Property - Patent around the DPV-001 cancer vaccine. This patent is owned by the Providence Health System and licensed to UbiVac
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Incyte; Merck
 
Alan Korman
Employment - Bluesphere Bio
 
Matthew Taylor
Honoraria - Bristol Myers Squibb Foundation; Exelixis
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)